Pioglitazone + TKI

Phase 2Small molecule

Pioglitazone + TKI is one of 3 small molecule programs targeting Chronic Myeloid Leukemia (CML). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Myeloid Leukemia (CML)Recruiting

Chronic Myeloid Leukemia (CML)Phase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Chronic Myeloid Leukemia (CML)

#DrugCompanyPhaseTrials

Velcade

SShilpa Grover, MD, MPH

Phase 1

1 2

NK Cells

SSouthwest Hospital, China

Phase 1

1 3

Pioglitazone + TKI

VVersailles Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Chronic Myeloid Leukemia (CML)

NCT02889003

Clinical

Trials by Indication[1]

Chronic Myeloid Leukemia (CML)1 trial

Combination Study of Pioglitazone and Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia Patients After Failure of a First TKIs Discontinuation Attempt in Order to Prepare a New Stop

Recruiting·VVersailles Hospital·Phase 2·NCT02889003·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pioglitazone + TKI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pioglitazone + TKI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pioglitazone + TKI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Versailles Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVersailles Hospital

Pioglitazone + TKI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Chronic Myeloid Leukemia (CML)1 trial

References

Drug Info

Quick Facts

Related News